Alemtuzumab Has Durable Efficacy on MRI Outcomes and Brain Atrophy Over 5 Years with Most Patients Free From Treatment for 4 Years: CARE-MS II Extension Study

作者:King J; Traboulsee A; Compston D A S; Hartung H P; Havrdova E; Selmaj K W; Margolin D H; Thangavelu K; Barkhof F
来源:8th Congress of the Pan-Asian-Committee-for-Research-and-Treatment-of-Multiple-Sclerosis (PACTRIMS), 2015-11-19 to 2015-11-21.